Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global phase III clinical trial of Bevacizumab Biosimilar (CT-P16)

Trial Profile

A global phase III clinical trial of Bevacizumab Biosimilar (CT-P16)

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Cancer; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Celltrion
  • Most Recent Events

    • 29 Aug 2018 New trial record
    • 10 Aug 2018 According to a Celltrion media release, the company has ubmitted its Clinical Trial Application for Phase 3 clinical study to the National Authority of Medicines and Health Products, I.P. (Infarmed) of Portugal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top